Signals
Breast Cancer Gets a New PI3K Pathway Option.
The FDA has approved gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation. The approval creates a new option, but only if mutation testing is routine and trusted.
Rare Epilepsy Moves Toward Treating the Cause
Digital Mental Health Still Has an Evidence Problem
Europe’s Mental Health Projects Move From Crisis Talk to Delivery Tools
Europe’s Epilepsy Rules Start Catching Up With Precision Treatment
SMA Screening Shows Precision Neurology Starts Before Symptoms
Post-Stroke Cognitive Screening Needs Local Tools
Europe’s Stroke Plan Turns Speed Into a Policy Test
Parkinson’s Research Moves From Tracking Progression to Defining Biology
MS Monitoring Starts Moving Beyond the MRI Bottleneck
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.